Structural Formula Gemcitabine (Gemcitabine 01)
Gemcitabine Injection, Powder, Lyophilized, For Solution
Product Images NDC 0409-0185
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gemcitabine (NDC 0409-0185). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Kaplan-meier Curve Of Progression Free Survival In Gemcitabine Plus Carboplatin Versus Carboplatin In Ovarian Cancer (n=356) (Gemcitabine 02)
Figure 2 (Gemcitabine 03)
The text is describing the results of a study or experiment that involved the drug Paclitaxel. The Log rank p-value is reported as 0.0001, which indicates statistical significance. The third line mentions something about "Time to Documented Disease Progression (Months)", but without further context it is difficult to determine what it means.*
Figure 3 (Gemcitabine 04)
This text contains statistical data related to the median survival time and survival probability for Gemcitabine/Cisplatin and Cisplatin, as well as statistical tests such as Logrank and Wilcoxon. However, it is not clear what type of study or research this data is from, as there is no additional context.*
Figure 4 (Gemcitabine 05)
This appears to be a graph displaying the "Fraction Surviving" over "Survival Time (months)" for a treatment named "Gemcitabine". The graph shows data points and a line representing the survival rate of individuals receiving Gemcitabine over the course of treatment. The graph is numbered by months and fractions, with the line starting at 0.8 at 10 months and decreasing to around 0.2 at 20 months.*
Hospira Logo (Gemcitabine 06)
Principal Display Panel (200 mg Vial Label)
Principal Display Panel (200 mg Vial Carton)
This is a product description of a drug called Gemcitabine, which is a Cytotoxic Agent. It comes in a single-dose vial containing 200mg Gemcitabine for Intravenous use only. The drug also contains 200mg Mannitol, and 125mg Sodium Acetate. The drug is reconstituted by adding 5 mL of 0.9% Sodium Chloride Injection to make a solution containing 38mg/mL. The solution should be administered within 24 hours and should be discarded if unused. The provided text also contains storage and usage instructions.*
Principal Display Panel (1 g Vial Label)
Principal Display Panel (1 g Vial Carton)
Gemcitabine for Injection, USP is a cytotoxic agent that comes in a single-dose vial. Each 1 g vial contains 1 g gemcitabine, 1 g mannitol, and 625 mg sodium acetate. It is recommended to check the package insert for complete product information. To reconstitute, add 25 L of 0.9% Sodium Chloride Injection and shake to dissolve. The solution should be administered within 24 hours and any unused portion should be discarded. The storage temperature before and after reconstitution should be between 20 - 25°C. Gemcitabine Hydrochloride is potentially cytotoxic, so be cautious when handling it.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
